Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CCR8 | P51685 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409880 | 1.00 | HRH3 (0.49) | HRH3CYP3A4CYP2D6CYP2C9CCR8 | |
| SCHEMBL12409841 | 0.93 | HRH3 (0.50) | HRH3CYP3A4CYP2D6CYP2C9CCR8 | |
| SCHEMBL12409812 | 0.87 | HRH3 (0.55) | HRH3CYP3A4CYP2D6CYP2C9KCNH2 | |
| SCHEMBL12409851 | 0.87 | HRH3 (0.55) | HRH3CYP3A4CYP2D6CYP2C9KCNH2 | |
| SCHEMBL12489975 | 0.86 | HRH3 (0.52) | HRH3CYP3A4CYP2D6CYP2C9CCR8 | |
| SCHEMBL12409879 | 0.84 | SMN1; SMN2 (0.35) | HRH3CYP3A4 | |
| SCHEMBL12409878 | 0.83 | HRH3 (0.31) | HRH3CYP3A4 | |
| SCHEMBL12409843 | 0.80 | HRH3 (0.53) | HRH3CYP3A4CYP2D6CYP2C9CCR8 | |
| SCHEMBL12494330 | 0.78 | HSD11B1 (0.33) | — | |
| SCHEMBL12495354 | 0.76 | HRH3 (0.57) | HRH3CYP3A4CYP2D6CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | MCCORMICK KEVIN D | 2011-07-07 | — | — | US | disclosed |
| WO-2010027567-A2 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | GPR119, TRPV1, NR3C2 | HRH3 2168/4885CYP3A4 226/4885CYP2D6 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.